leukocyte-suppressing anti-inflammatory drugs (Inflazyme)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Nameleukocyte-suppressing anti-inflammatory drugs (Inflazyme)
Drug Alias NameILP-12 series (Inflazyme/sanofi-aventis)IPL-12a85MELSAIDS (Inflazyme/sanofi-aventis)LSAIDs (Inflazyme/Aventis)LSAIDs (Biolipox) +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukocytes inhibitors
TargetsUpdating
Therapy Area/IndicationsInflammationRespiratory Tract Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInflazyme Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAventis Pharmaceuticals IncInflazyme Pharmaceuticals Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsInflammationRespiratory Tract Infections

Other Information

ATC CodeN/A
Related LinksN/A